Stewart and co-workers evaluated the safety and therapeutic effects of orally administered AKST4290 in treatment-naive patients with neovascular age-related macular degeneration. In this prospective, multicenter, open-label Phase 2a pilot clinical study, 30 patients with newly diagnosed neovascular age-related macular degeneration self-administered AKST4290 (400 mg) orally twice daily for 6 weeks. Stewart and co-workers coluded that, in patients with treatment-naive neovascular age-related macular degeneration, 6 weeks of orally administered AKST4290 was well-tolerated and associated with improved best-corrected visual acuity scores. AKST4290 is being developed as a potential oral alternative for the treatment of neovascular age-related macular degeneration, and further studies are warranted.
Stewart MW, Garg S, Newman EM, et al. Safety and therapeutic effects of orally administered akst4290 in newly diagnosed neovascular age-related macular degeneration. Retina. 2022;42:1038-1046. https://pubmed.ncbi.nlm.nih.gov/35537111/
